Evogene shares rise 13.46% premarket after licensing microbiome cancer therapy BMC128 to Shanghai Lishan Biopharmaceuticals.

Evogene surged 13.46% in premarket trading following the announcement of an exclusive licensing agreement with Shanghai Lishan Biopharmaceuticals for BMC128, a microbiome-based cancer therapy. The deal grants Lishan global rights to develop, manufacture, and commercialize BMC128, which is completing Phase 1 trials with promising safety and efficacy data in renal and lung cancer patients. Evogene’s subsidiary, Biomica, will receive milestone payments and royalties, positioning the partnership as a potential catalyst for value creation. The collaboration aligns with Evogene’s focus on microbiome innovation and leverages Lishan’s clinical development expertise, bolstering investor confidence in the therapy’s future regulatory and commercial prospects.